Bio-Nanoparticles for HIV Antigen Delivery

用于 HIV 抗原递送的生物纳米颗粒

• 批准号: 8653936
• 负责人: OTTO O YANG
• 金额: $ 19.25万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-19 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8653936
• 关键词: AIDS Vaccines; Adenoviruses; Amino Acid Sequence; Animal Model; Antigens; Attenuated; Autologous; Biological; Biological Assay; CD8B1 gene; Cells; Cytoplasm; Cytotoxic T-Lymphocytes; DNA; Development; Drug resistance; Eukaryotic Cell; Face; Fowlpox; Generations; HIV Antigens; HIV-1; Histocompatibility; Human; Immune; Immune system; Immunity; Infection; Infection prevention; Interferons; Left; Life; Mucous Membrane; Negative Staining; Pathway interactions; Peptide Sequence Determination; Peptides; Prevention; Preventive; Protein Subunits; Proteins; RNA Sequences; Recombinants; Ribonucleoproteins; Risk; Rome; Safety; Serotyping; Structure; Subunit Vaccines; Text; Thinking; Toxic effect; Transmission Electron Microscopy; Untranslated RNA; Vaccine Design; Vaccines; Vaccinia; Vaccinium; Viral; Viral Proteins; Viremia; Virus; Work; arm; carcinogenicity; immune activation; immunogenic; immunogenicity; killings; memory CD4 T lymphocyte; nanoparticle; neutralizing antibody; novel strategies; optimism; public health relevance; response; success; therapeutic vaccine; vaccine candidate; vector; vector vaccine; viral resistance

DESCRIPTION (provided by applicant): It is likely that a CTL-eliciting component will be required for an effective HIV-1 vaccine. To date, only the recombinant adenovirus-5 vaccine has been a candidate for such a component, but it faced significant issues with vector immunity and had unknown capacity to access mucosal tissues. Nanoparticles offer some advantages as vaccine vectors, but face problems with immunogenicity, carcinogenicity, and manufacturing quality. This proposal explores the use of biological nanoparticles ("vaults") composed of autologous human proteins, loaded with HIV-1 sequences to serve as a vaccine. Vaults have been shown to be immunogenic for CTL responses and access the mucosal immune system. Additionally, they are composed of self-proteins that are normally found in the cytoplasm and therefore should not be immunogenic or carcinogenic, and are readily manufactured with consistent quality. The two aims will be: Aim 1: To create targeted vaults carrying conserved HIV-1 protein sequences; Aim 2: To confirm the immunogenicity of the vaults in systemic and mucosal immune compartments.

描述（由申请人提供）：一种有效的HIV-1疫苗可能需要ctl诱导成分。迄今为止，只有重组腺病毒-5疫苗是这种成分的候选物，但它面临着载体免疫的重大问题，并且对粘膜组织的进入能力未知。纳米粒子作为疫苗载体具有一定的优势，但也面临着免疫原性、致癌性和制造质量等问题。